Clinical trial ZEPHIR
A phase II prospective imaging study evaluating the utility of pretreatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast cancer unlikely to benefit from a novel anti-HER2 therapy : T-DM1
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Oui |
| Sponsor | Institut Jules Bordet |
| EudraCT Identifier | 2011-00543-739 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01420146 |
| Inclusion criteria | *HER2+ invasive carcinoma of the breast *progressive disease with at least 2 non-bone 'target' metastatic lesions*biopsy of a metastatic site before inclusion |
| Last update |